

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): February 28, 2022

GoodRx Holdings, Inc.
(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-39549
(Commission
File Number)

47-5104396
(IRS Employer
Identification No.)

2701 Olympic Boulevard
Santa Monica, CA 90404
(Address of Principal Executive Offices) (Zip Code)

(855) 268-2822
(Registrant's telephone number, including area code)

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbols	Name of each exchange on which registered
Class A Common Stock, \$0.0001 par value per share	GDRX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On February 28, 2022, GoodRx Holdings, Inc. (the “Company”), announced the Company’s financial results for the three months and year ended December 31, 2021. The full text of the press release and letter to shareholders issued in connection with the announcement are furnished as Exhibits 99.1 and 99.2, respectively, to this report.

The information in Item 2.02 and Exhibits 99.1 and 99.2 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1* [Press Release, dated February 28, 2022.](#)

99.2* [Letter to Shareholders, dated February 28, 2022.](#)

104 Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document.

* Furnished herewith.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GOODRX HOLDINGS, INC.

By: /s/ Karsten Voermann

Name: Karsten Voermann

Title: Chief Financial Officer

Date: February 28, 2022

GoodRx Releases Fourth Quarter and Full Year 2021 Financial Results

SANTA MONICA, Calif. February 28, 2022 – GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, has released its fourth quarter and full year 2021 financial results and posted a letter to shareholders on the Overview page of its investor relations website at <https://investors.goodrx.com>.

GoodRx management will host a conference call and webcast today at 2:00 pm. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company's business outlook.

Fourth Quarter and Full Year 2021 Results Conference Call

Date: Monday, February 28, 2022
Time: 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time
Webcast: <https://investors.goodrx.com> (live and replay)
Dial-in number: (833) 614-1447

Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company's investor relations website at <https://investors.goodrx.com> for at least 30 days.

About GoodRx

GoodRx is a leading consumer-focused digital healthcare platform. Our technology delivers strong savings, trusted information and access to care to make healthcare affordable and convenient for all Americans. Since 2011, we have helped consumers save over \$35 billion and are one of the most downloaded medical apps over the past decade.

Investor Contact

GoodRx
Whitney Notaro
wnotaro@goodrx.com

Press Contact

GoodRx
Lauren Casparis
lcasparis@goodrx.com

Q4 2021



Letter to Shareholders

February 28, 2022



GoodRx **helps Americans** get the healthcare they need at a price they can afford.

“ GoodRx helps my patients pay less for prescriptions and saves me time. It’s a better experience for all.

Sharon Orrange, MD, MHS, FACP
Internal Medicine
The Doctors of USC Beverly Hills



Dr. Orrange is a GoodRx advisor.

GoodRx + healthcare professionals. A massive win-win.

It's been more than a decade, but we still vividly remember those early days right after we launched the GoodRx website and app. Not everyone understood our idea of helping patients find affordable care. Some assumed insurance would cover everything; others in the industry dismissed our initial focus on generic drugs, saying "all the action" was in brand.

But one constituency embraced us from the beginning — America's physicians and health care professionals. Every day, they were hearing from patients who couldn't afford the medications they prescribed. Every day, they witnessed the hard choices their patients were making, and saw the consequences of patients who chose not to fill prescriptions or get care because it simply cost too much.

Today, our partnership with America's healthcare providers is stronger and deeper than ever. Over 700,000 prescribers have used GoodRx since June 2021,¹ and over 400,000 physician offices actively distribute our materials.² Over 2 million prescribers have a patient who has used GoodRx,² and our exceptionally high provider NPS of 90³ is a testament to the value we bring.

In the fourth quarter, we began offering a new and improved GoodRx for Providers platform built specifically for physicians, providing unique features while giving us the opportunity to monetize what we expect to be one of the largest provider platforms in the U.S. Early adoption has been strong, with over 90% of providers opting into this new mode, which represents over 80,000 HCPs and growing.⁴ Within weeks of launch, we closed the first of what we expect to be many deals with pharma manufacturers who want to engage with our massive provider network.

Throughout 2021, GoodRx helped millions of Americans navigate their care and realize greater savings than ever. We remained focused on our strategic priorities for the year and achieved record revenue, record users and record visitors to our website. Underpinning these results is a virtuous flywheel that continues to propel us: the greater our impact, the stronger our performance.

Our pharma manufacturer solutions offering delivered another quarter of explosive growth, growing 4x year-over-year, capitalizing on the fact that 20% of searches on our platform are for brand drugs. We finished the year with net revenue retention of over 150%,⁵ and working with 19 of the top 20 pharma manufacturers and over 140 brands. We also built a very robust pipeline for 2022, setting a foundation for strong and sustainable growth of this offering. With the combination of GoodRx for Providers

and our consumer offerings, we believe GoodRx delivers a truly unparalleled digital healthcare platform, and a unique ability for us and for our partners, especially pharma manufacturers, to educate, influence, and serve providers and patients in a coordinated fashion.

We see significant opportunities to build on our 2021 growth and success to deliver a very strong 2022, reaching more consumers and providers and bringing more value to each stage of the healthcare journey.

Strategic priorities for 2022:

- 1 Increase brand awareness and reach** to help more consumers understand how we can help them navigate their healthcare journey.
- 2 Strengthen our healthcare provider relationships** by expanding the HCP value proposition and continuing to make GoodRx a destination that meets providers' unique needs and helps achieve better patient outcomes.
- 3 Deepen our relationships with consumers** by offering relevant, timely and actionable services, advice and content that enhance engagement.
- 4 Build or acquire new platform capabilities** that create the foundation for additional services and value we can offer consumers, HCPs and pharma manufacturers.

We are excited about the opportunities in 2022 and beyond. When you're a patient's trusted advocate, you've earned the right to help patients navigate their entire healthcare journey. We believe there are still many adjacent categories for GoodRx to enter within the massive \$4 trillion U.S. healthcare market, and we will approach each opportunity with the goal of making healthcare easier, more transparent, and more affordable for Americans.



Doug Hirsch

Co-Founders & Co-CEOs, GoodRx



Trevor Bezdek

¹ Per DMD / IQVIA data.

² Based on internal data.

³ Provider NPS based on September 2021 survey on the GoodRx website.

⁴ The new mode is being rolled out gradually so only a subset of providers have had a chance to opt in.

⁵ Net revenue retention compares total revenue generated from all pharma manufacturer solutions clients in the year-to-date period ended December 31, 2021, to the total revenue generated from the same clients in the year-to-date period ended December 30, 2020, excluding all new client relationships established since December 31, 2020.

Q4 / FY 2021 Highlights

	Revenue	Net Loss	Adjusted EBITDA ²	Adjusted Net Income ²
Q4 '21	\$213.3M +39% YOY	(\$39.9M)* (18.7%) Margin ¹	\$62.3M 29.2% Margin ¹	\$40.5M 19.0% Margin ¹
FY '21	\$745.4M +35% YOY	(\$25.3M)** (3.4%) Margin ¹	\$229.6M 30.8% Margin ¹	\$147.0M 19.7% Margin ¹

* Q4 '21 Net Loss was impacted by a \$45.8M provision for income taxes driven by a \$52.4M non-cash valuation allowance against our net deferred tax assets and \$33.3M of stock-based compensation expense, \$16.8M of which related to the non-recurring co-CEOs' awards made in connection with our IPO.

** FY '21 Net Loss was impacted by a \$15.1M provision for income taxes driven principally by the \$52.4M non-cash valuation allowance described above, and \$160.5M of stock-based compensation expense, \$90.9M of which related to the non-recurring co-CEOs' awards made in connection with our IPO.



Monthly Active Consumers³



Subscription Plans⁴



Financial Data

(dollars in millions)

	Q4 '21	Q4 '20	CHANGE	FY '21	FY '20	CHANGE
Revenue	\$213.3	\$153.5	39%	\$745.4	\$550.7	35%
Net Loss	(\$39.9)	(\$298.3)	(87%)	(\$25.3)	(\$293.6)	(91%)
Adjusted Net Income ²	\$40.5	\$32.2	26%	\$147.0	\$133.3	10%
Adjusted EBITDA ²	\$62.3	\$49.1	27%	\$229.6	\$203.4	13%
Adjusted EBITDA Margin ²	29.2%	32.0%	(280 bps)	30.8%	36.9%	(610 bps)
Cash Provided by Operating Activities	\$49.8	\$14.9	235%	\$178.8	\$131.3	36%

¹ Net Margin, Adjusted EBITDA Margin, and Adjusted Net Margin represent Net Loss, Adjusted EBITDA, and Adjusted Net Income divided by Revenue, respectively.

² Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Net Margin are non-GAAP financial measures and are presented for supplemental informational purposes only. Refer to the Non-GAAP Financial Measures section below for definitions, additional information, and a reconciliation to the most directly comparable GAAP measures.


³ Monthly Active Consumers (MACs) refers to the number of unique consumers who have used a GoodRx code to purchase a prescription medication in a given calendar month and have saved money compared to the list price of the medication. A unique consumer who uses a GoodRx code more than once in a calendar month to purchase prescription medications is only counted as one Monthly Active Consumer in that month. A unique consumer who uses a GoodRx code in two or three calendar months within a quarter will be counted as a Monthly Active Consumer in each such month. Monthly Active Consumers do not include subscribers to our subscription offerings, consumers of our pharma manufacturer solutions offering, or consumers who use our telehealth offerings. When presented for a period longer than a month, Monthly Active Consumers are averaged over the number of calendar months in such period. Monthly Active Consumers from acquired companies are only included beginning in the first full quarter following the acquisition. RxSaver Monthly Active Consumers have been included as of the beginning of the third quarter of 2021, and are estimated due to incomplete consumer information.

⁴ Represents the ending subscription plan balance across both of our subscription offerings, GoodRx Gold and Kroger Savings Club.

Business Updates


GoodRx launches enhanced GoodRx for Providers platform, offering a more customized experience for healthcare providers with tools to support patients throughout their healthcare journey

For the past 10 years, GoodRx has focused on building the strongest, most trusted consumer brand in healthcare. While developing trusted relationships with millions of Americans, we also generated phenomenal trust with the healthcare provider community. This is evidenced by our increased provider NPS, which is now up to 90. Our simple and honest solutions help patients get the healthcare they need at a price they can afford while also reducing the administrative burden on providers and their staff. In a July 2021 internal survey, 89% of providers said GoodRx saves them and their staff time on administrative tasks, 93% said GoodRx helps their patients with medication access and 88% said GoodRx helps their patients with medication adherence. In short, our prescription-related offerings ultimately help providers do what they do best: help their patients.



We believe there is an enormous opportunity for us to meet providers' unique needs with innovative solutions while helping them achieve better patient outcomes


GoodRx understands the patient journey given our extensive experience not just in the prescription market, but through GoodRx Care. With that deep experience as our foundation, we've been reimagining the way patients and HCPs interact with the healthcare system. And, as a scaled platform where both patients and HCPs engage with us at the same stage of the patient's healthcare journey, we believe there is an enormous opportunity for us to meet providers' unique needs with innovative solutions while helping them achieve better patient outcomes. To capture this opportunity and further expand our relationships with providers, we created a new and improved GoodRx for Providers platform in the fourth quarter, through our recently launched Provider mode. GoodRx for Providers is our dedicated provider platform offering HCPs a more customized experience and equipping them with the tools they need to support their patients throughout their healthcare journey.



Since we started tracking DMD / IQVIA data in June 2021, over 700,000 prescribers have used the GoodRx platform — spanning broadly across specialties from oncology to primary care. We have been introducing our new Provider mode gradually to a subset of the providers who visit GoodRx and have seen strong adoption, with over 90% of providers who have been introduced opting into this new mode, which represents over 80,000 HCPs and growing. We believe this high rate of adoption without any off-platform marketing underscores its highly differentiated value for providers, and points to its competitive superiority.

As part of this launch, we redesigned our prescription savings flow with the provider in mind, offering more streamlined navigation, and focusing on their needs. These changes have significantly increased provider engagement. So far, we've seen providers on the platform sharing discounts with patients at a much higher rate than before — almost 2x more frequently based on early results. We've helped our huge provider base, which was already highly engaged, become significantly more effective at driving use of our prescription-related offerings, and we help providers reduce the amount of time they spend trying to provide access to medications for their patients, which is estimated to be almost 15 hours a week by the American Medical Association.

Providers can share discounts with patients anonymously



Providers are also turning to GoodRx as a source for editorial content. While price searches and product savings drive significant provider engagement, we have seen increasing provider interest in our GoodRx Health content. In 2021, we added thousands of new articles and videos, more than tripling the size of the GoodRx Health content library. Providers on the platform are actively searching GoodRx for articles and content reviewed by medical and editorial experts and we plan to make sharing these resources even more seamless in HCP mode. This engagement further validates our focus on GoodRx Health and lends itself to a more curated content experience for providers in the future.

We believe the runway and opportunities to continue to address provider needs are massive. We are actively developing novel and innovative platform features to grow provider engagement, reach and scale and are excited about the opportunity to forge deeper relationships between providers and others, like pharma manufacturers, in the healthcare ecosystem. We plan to add features which will equip providers with comprehensive cost information at the point of prescribing to help their patients start and stay on their prescribed medications — whether they're uninsured, underinsured, or fully-insured. We are also focused on developing a host of prescribing and workflow tools to help make the most of providers' time by reducing their administrative burden so they can focus on patient care. Additionally, we're working on new ways for providers to interact with pharma representatives, medical science liaisons and key opinion leaders to help their patients learn about, start and stay on their prescribed therapies.


In the first quarter of 2022, we added to our provider-specific solutions with the acquisition of flipMD, a marketplace connecting practicing physicians with organizations seeking on-demand medical expertise. We believe flipMD has exciting capabilities that will both expand our engagement with healthcare providers and the services available through our pharma manufacturer solutions offering, continuing to differentiate our offering from alternatives.

Closed first pharma manufacturer solutions deals specifically targeting HCPs

GoodRx for Providers allows us to not only drive growth in our prescription-related offerings, but also expand our pharma manufacturer solutions offering by addressing an even greater share of the \$30 billion spent annually on pharma marketing. In recent years, pharma provider marketing has seen a shift from in-person to digital-first promotions, which has been accelerated by COVID-19. We believe GoodRx is well positioned to benefit from this trend. In fact, we grew our pharma manufacturer solutions offering an incredible 4x year-over-year in the fourth quarter with net revenue retention of over 150%. We finished the year working with 19 of the top 20 manufacturers and over 140 brands.

We're also excited to announce that we closed our first pharma manufacturer deals specifically targeting HCPs, with two top manufacturers, in the fourth quarter. GoodRx for Providers enables pharma manufacturers to reach a large, high-intent audience at a key point in the provider and patient journey. Providers consult GoodRx for Providers at the point of prescribing to help their patients with access and affordability challenges. GoodRx for Providers, alongside our consumer savings solutions and GoodRx Health, provide essential tools for Americans across the healthcare journey. At the same time, our pharma manufacturer solutions offering creates a compelling opportunity for pharma manufacturers to connect with both patients and providers in a highly coordinated manner across GoodRx's trusted platforms.

Potential future state



We are in the early stages of an exciting opportunity

We believe that our alignment with providers, and our mutual dedication to helping their patients, is a fundamental and flourishing part of our success. Physicians and healthcare professionals trust us, with over 2 million prescribers that have a patient that has used GoodRx and a very high provider NPS of 90. With GoodRx for Providers, providers are top of mind, as we continue to build on that trust, increase engagement and strengthen relationships with the provider community. With the combination of GoodRx for Providers and our consumer offerings, we believe GoodRx delivers a truly unparalleled digital healthcare platform, and

a unique ability for us and for our partners, especially pharma manufacturers, to educate, influence, and serve providers and consumers in a coordinated fashion. Although we've made a lot of progress over the past decade, we are just getting started — we see tremendous opportunity ahead to continue to revolutionize healthcare for Americans.

GoodRx announces \$250 million share repurchase program

We are confident in the current and future strength of our business, and we are committed to creating long-term, sustainable value for our shareholders. In addition to making investments to increase our brand awareness and reach, strengthen our HCP relationships, deepen our relationship with consumers, and build or acquire new platform capabilities, among others, we recently announced our Board's authorization of a share repurchase program.

On February 23, 2022, our Board authorized the repurchase of up to an aggregate of \$250 million of our Class A Common Stock. Repurchases under the program may be made in the open market, in privately negotiated transactions or otherwise, with the amount and timing of repurchases to be determined at our discretion, depending on market conditions and corporate needs. Open market repurchases will be structured to occur in accordance with applicable federal securities laws, including within the pricing and volume requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. We may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of our shares under this authorization. This program does not obligate us to acquire any particular amount of Class A Common Stock and may be modified, suspended or terminated at any time at the discretion of our Board through February 23, 2024.

We expect to fund the repurchases with our existing cash and cash equivalents, working capital, cash flow from operations, or funds available through various borrowing arrangements.

Financials

Prescription Transactions Revenue

Fourth quarter Prescription Transactions Revenue grew 21% year-over-year to \$158.8 million, driven by a 14% year-over-year increase in MACs and a continued increase in revenue per MAC. We believe the growth of our prescription transactions offering continued to be impacted by COVID-19 headwinds, as healthcare utilization challenges continue and the cumulative impact of almost two years of reduced prescription starts — and therefore reduced refills — impacted new and returning users.

Full year Prescription Transactions Revenue grew 22% year-over-year in 2021, reaching \$593.4 million.

(in millions)



Subscription Revenue¹

Fourth quarter Subscription Revenue grew 79% year-over-year to \$17.4 million, driven by a 51% increase in the number of subscription plans, as well as a favorable change in subscription plan mix.

Full year Subscription Revenue grew 104% year-over-year in 2021, reaching \$59.9 million.

(in millions)



Other Revenue¹

Fourth quarter Other Revenue grew 196% year-over-year to \$37.1 million, driven primarily by higher revenue from our pharma manufacturer solutions offering which grew 4x year-over-year.

Full year Other Revenue grew 179% year-over-year in 2021, reaching \$92.1 million.

(in millions)



¹ Beginning in Q2 2021, Subscription Revenue is disclosed separately from Other Revenue, which now primarily consists of revenue generated from our pharma manufacturer solutions and Telehealth offerings. Prior period amounts have been recast to conform to the current period presentation.

Note: Due to rounding, numbers presented may not add up precisely to the totals provided.

Net Income (Loss)


Fourth quarter Net Loss was \$39.9 million, compared to a Net Loss of \$298.3 million in the fourth quarter of 2020. The year-over-year change was driven primarily by a \$263.2 million decrease in stock-based compensation expense and related payroll taxes, primarily related to the non-recurring Co-Chief Executive Officers' awards made in connection with our IPO. The decrease was also driven by a \$41.7 million charge related to a charitable stock donation in support of our philanthropic endeavors made in the fourth quarter of 2020. These were partially offset by an increase to our provision for income taxes, which was a \$45.8 million expense in the fourth quarter of 2021 compared to a \$7.4 million benefit in the comparable period last year. Tax expense in the fourth quarter of 2021 included a \$52.4 million valuation allowance charge against our net deferred tax assets, driven primarily by significant excess tax benefits realized since our IPO, which we anticipate continuing based on the substantial year-end balance of outstanding stock options granted before our IPO.

In addition, the change was driven by business growth, partially offset by an increase in sales and marketing spend, continued investments in product development and technology, and our investments in our general and administrative infrastructure.

Fourth quarter Net Margin was (18.7%) compared to (194.3%) last year, a 175.6 percentage point year-over-year improvement.

Net Loss for the full year was \$25.3 million, compared to a Net Loss of \$293.6 million in 2020. Full year Net Margin was (3.4%) compared to (53.3%) in the prior year.

(in millions)



Adjusted EBITDA

Fourth quarter Adjusted EBITDA grew 27% to \$62.3 million compared to \$49.1 million in the fourth quarter of 2020. Adjusted EBITDA Margin was 29.2%, a 280 basis point year-over-year decrease. The margin decrease was driven by investments in our general and administrative infrastructure, particularly in relation to operating as a public company for our first full year, continued investments in product development and technology, and an increase in sales and marketing spend.

Our full year Adjusted EBITDA grew 13% to \$229.6 million. Our full year Adjusted EBITDA Margin was 30.8%, compared to 36.9% in 2020.

(in millions)



Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP financial measures and are presented for supplemental informational purposes only. Refer to the Non-GAAP Financial Measures section below for definitions, additional information, and a reconciliation to the most directly comparable GAAP measures.

Note: Due to rounding, numbers presented may not add up precisely to the totals provided.

Adjusted Net Income

Fourth quarter Adjusted Net Income grew 26% to \$40.5 million compared to \$32.2 million in the fourth quarter of 2020.

Our full year Adjusted Net Income grew 10% year-over-year in 2021, reaching \$147.0 million.

(in millions)



Adjusted Net Income is a non-GAAP financial measure and is presented for supplemental informational purposes only. Refer to the Non-GAAP Financial Measures section below for definitions, additional information, and a reconciliation to the most directly comparable GAAP measures.

Net Cash Provided by Operating Activities

Fourth quarter Net Cash Provided by Operating Activities was up 235% year-over-year to \$49.8 million, made up of Net Loss of \$39.9 million, adjusted primarily by our non-cash valuation allowance against our net deferred tax assets of \$52.4 million and stock-based compensation expense of \$33.3 million.

The year-over-year increase, as well as the sequential decline in 2020 were due primarily to the timing of tax payments in 2020, the vast majority of which were made in the third and fourth quarters. These tax payments included payroll taxes related to the non-recurring Co-Chief Executive Officers' equity awards and the exercise of stock options around and after our September 2020 IPO, as well as income tax payments as the extension, first, and second quarter payments were deferred to the third quarter.

(in millions)



Note: Due to rounding, numbers presented may not add up precisely to the totals provided.

Guidance

Our outlook for the first quarter and full year 2022 is as follows:

	Q1 2022 Guidance	
Revenue	Approx. \$200M	Approx. 25% year-over-year growth
Adjusted EBITDA Margin	28% – 30%	

	FY 2022 Guidance	
Revenue	Approx. 23% year-over-year growth	
Adjusted EBITDA Margin	31% – 33%	

Adjusted EBITDA Margin is a non-GAAP financial measure and is presented for supplemental informational purposes only. We have not reconciled our Adjusted EBITDA Margin guidance to GAAP net income or loss margin, or Net Margin, because we do not provide guidance for GAAP Net Margin due to the uncertainty and potential variability of stock-based compensation expense, acquired intangible assets and related amortization and income taxes, which are reconciling items between Adjusted EBITDA Margin and GAAP Net Margin. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measure. However, such items could have a significant impact on GAAP Net Margin.

Forward-Looking Statements

This shareholder letter contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this shareholder letter that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future operations and financial results, the benefits to consumers or GoodRx of our agreements with partners, customers and other entities, the impact and usage of GoodRx for Providers or GoodRx Health, underlying trends in our business, our market opportunity, the growth of GoodRx for Providers, our telehealth and manufacturer solutions businesses, the benefits of cross-selling products, competitiveness of our prices, especially in relation to insurance, the growth of our relationships with industry participants and partners, the anticipated impact of COVID-19 on our business, post-COVID-19 trends, our potential for growth, our stock repurchase program, demand for our offerings, our strategic growth priorities, including our 2022 priorities, and future offerings, future financial results, collaborations and partnerships with third parties, and our strategy. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks related to our limited operating history and early stage of growth; our ability to achieve broad market education and change consumer purchasing habits; our ability to continue to attract, acquire and retain consumers in a cost-effective manner; our reliance on our prescription transactions offering and ability to expand our offerings; changes in medication pricing and pricing structures; our inability to control the categories and types of prescriptions for which we can offer savings or discounted prices; our reliance on a limited number of industry participants; the competitive nature of industry; risks related to pandemics, epidemics or outbreak of infectious disease, including the COVID-19 pandemic; the accuracy of our estimate of our total addressable market and other operational metrics; the development of the telehealth market; our ability to maintain and expand a network of skilled telehealth providers; risks related to negative media coverage; our ability to respond to changes in the market for prescription pricing and to maintain and expand the use of GoodRx codes; our ability to maintain positive perception of our platform and brand; risks related to any failure to maintain effective internal control over financial reporting; risks related to use of social media, emails, text messages and other messaging channels as part of our marketing strategy; our ability to accurately forecast revenue and appropriately plan our expenses in the future; risks related to information technology and cyber-security; compliance with government regulation of the internet, e-commerce and data and other regulations; our ability to utilize our net operating loss carryforwards and certain other tax attributes; our ability to attract, develop, motivate and retain well-qualified employees; risks related to general economic factors, natural disasters or other unexpected events; risks related to our acquisition strategy; risks related to our debt arrangements; interruptions or delays in service on our apps or websites; our reliance on third-party platforms to distribute our platform and offerings; our reliance on software as-a-service technologies from third parties; systems failures or other disruptions in the operations of these parties on which we depend; changes in consumer sentiment or laws, rules or regulations regarding tracking technologies and other privacy matters; the increasing focus on environmental sustainability and social initiatives; risks related to our intellectual property; risks related to operating in the healthcare industry; risks related to our organizational structure; risks related to fluctuations in our tax obligations and effective income tax rate which could materially and adversely affect our results of operations; as well as the other important factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2021, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this shareholder letter. Any such forward looking statements represent management's estimates as of the date of this shareholder letter. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Financial Statements

GoodRx Holdings, Inc.
Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except par values)

	December 31, 2021	December 31, 2020
Assets		
Current assets		
Cash and cash equivalents	\$ 941,109	\$ 968,691
Restricted cash	—	2,900
Accounts receivable, net	118,080	68,729
Prepaid expenses and other current assets	29,638	46,048
Total current assets	1,088,827	1,086,368
Property and equipment, net	21,612	23,057
Goodwill	329,696	261,116
Intangible assets, net	88,791	36,919
Capitalized software, net	44,987	19,800
Operating lease right-of-use assets	27,705	27,712
Deferred tax assets, net	—	13,117
Other assets	6,007	2,025
Total assets	\$ 1,607,625	\$ 1,470,114
Liabilities and stockholders' equity		
Current liabilities		
Accounts payable	\$ 17,501	\$ 10,291
Accrued expenses and other current liabilities	50,732	37,692
Current portion of debt	7,029	7,029
Operating lease liabilities, current	5,851	4,539
Total current liabilities	81,113	59,551
Debt, net	655,858	659,888
Operating lease liabilities, net of current portion	33,592	33,467
Deferred tax liabilities, net	244	—
Other liabilities	5,138	5,849
Total liabilities	775,945	758,755
Stockholders' Equity		
Preferred stock	—	—
Common stock, \$0.0001 par value	40	39
Additional paid-in capital	2,247,347	2,101,773
Accumulated deficit	(1,415,707)	(1,390,453)
Total stockholders' equity	831,680	711,359
Total liabilities and stockholders' equity	\$ 1,607,625	\$ 1,470,114

GoodRx Holdings, Inc.
Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except per share amounts)

	Three Months Ended December 31,		Year Ended December 31,	
	2021	2020	2021	2020
Revenue	\$ 213,256	\$ 153,544	\$ 745,424	\$ 550,700
Costs and operating expenses:				
Cost of revenue, exclusive of depreciation and amortization presented separately below	13,927	9,204	46,716	29,587
Product development and technology	35,060	23,683	125,860	61,816
Sales and marketing	106,491	74,940	370,217	255,135
General and administrative	35,374	340,753	154,686	461,451
Depreciation and amortization	10,648	4,404	34,539	18,430
Total costs and operating expenses	201,500	452,984	732,018	826,419
Operating income (loss)	11,756	(299,440)	13,406	(275,719)
Other expense, net:				
Other income, net	—	(2)	—	(22)
Interest income	(17)	(20)	(59)	(160)
Interest expense	5,903	6,216	23,642	27,913
Total other expense, net	5,886	6,194	23,583	27,731
Income (loss) before income taxes	5,870	(305,634)	(10,177)	(303,450)
Income tax (expense) benefit	(45,784)	7,360	(15,077)	9,827
Net loss	\$ (39,914)	\$ (298,274)	\$ (25,254)	\$ (293,623)
Net loss attributable to common stockholders:				
Basic	\$ (39,914)	\$ (298,274)	\$ (25,254)	\$ (293,623)
Diluted	\$ (39,914)	\$ (298,274)	\$ (25,254)	\$ (293,623)
Loss per share:				
Basic	\$ (0.10)	\$ (0.74)	\$ (0.06)	\$ (1.07)
Diluted	\$ (0.10)	\$ (0.74)	\$ (0.06)	\$ (1.07)
Weighted average shares used in computing loss per share:				
Basic	414,068	401,459	409,981	274,696
Diluted	414,068	401,459	409,981	274,696
Stock-based compensation included in costs and operating expenses:				
Cost of revenue	\$ 258	\$ 86	\$ 798	\$ 184
Product development and technology	8,434	6,165	35,090	10,937
Sales and marketing	4,487	3,027	20,645	8,789
General and administrative	20,101	276,803	103,929	377,375

GoodRx Holdings, Inc.
Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

	Year Ended December 31,	
	2021	2020
Cash flows from operating activities		
Net loss	\$ (25,254)	\$ (293,623)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization	34,539	18,430
Amortization of debt issuance costs	3,445	3,390
Non-cash operating lease expense	3,102	4,478
Stock-based compensation expense	160,462	397,285
Change in fair value of contingent consideration	—	2,068
Deferred income taxes	12,851	(10,910)
Loss on abandonment and impairment of operating lease assets	1,430	961
Charitable stock donation	—	41,721
Changes in operating assets and liabilities, net of effects of business acquisitions		
Accounts receivable	(43,949)	(16,139)
Prepaid expenses and other assets	17,060	(40,935)
Accounts payable	4,207	2,154
Accrued expenses and other current liabilities	14,001	15,010
Operating lease liabilities	(2,404)	4,576
Other liabilities	(711)	2,875
Net cash provided by operating activities	178,779	131,341
Cash flows from investing activities		
Purchase of property and equipment	(4,571)	(20,553)
Acquisitions, net of cash acquired	(140,268)	(55,793)
Capitalized software	(29,886)	(15,271)
Investment in minority equity interest	(4,008)	—
Net cash used in investing activities	(178,733)	(91,617)
Cash flows from financing activities		
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions	—	891,793
Proceeds from private placement with a related party	—	100,000
Proceeds from long-term debt	—	28,000
Payments on long-term debt	(7,029)	(35,029)
Payment of debt issuance costs and prepayment penalty	—	(1,306)
Payment for contingent consideration	(832)	—
Payments of initial public offering issuance costs	—	(4,937)
Proceeds from exercise of stock options	35,021	5,343
Proceeds from early exercise of stock options	—	667
Employee taxes paid related to net share settlement of equity awards	(57,688)	(78,714)
Net cash (used in) provided by financing activities	(30,528)	905,817
Net change in cash, cash equivalents and restricted cash	(30,482)	945,541
Cash, cash equivalents and restricted cash		
Beginning of period	971,591	26,050
End of period	\$ 941,109	\$ 971,591

Non-GAAP Financial Measures

Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Net Margin, Adjusted Earnings Per Share and Adjusted Operating Income are supplemental measures of our performance that are not required by, or presented in accordance with, U.S. GAAP. We also present each cost and operating expense on our consolidated statements of operations on an adjusted basis. Collectively, we refer to these non-GAAP financial measures as our “Non-GAAP Measures”.

We define Adjusted EBITDA for a particular period as net income or loss before interest, taxes, depreciation and amortization, and as further adjusted for acquisition related expenses, cash bonuses to vested option holders, stock-based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing related expenses, loss on abandonment and impairment of operating lease assets, charitable stock donation and other income or expense, net, as applicable for the periods presented. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of revenue.

We define Adjusted Net Income for a particular period as net income or loss adjusted for, as applicable for the periods presented, amortization of intangibles related to acquisitions, acquisition related expenses, stock-based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing related expenses, loss on abandonment and impairment of operating lease assets, charitable stock donation, and as further adjusted for estimated income tax on such adjusted items. Our adjusted taxes also excludes (i) the valuation allowance recorded against our net deferred tax assets that was recognized in accordance with GAAP, and (ii) all tax benefits/expenses resulting from excess tax benefits/deficiencies in connection with stock-based compensation. Adjusted Net Margin is Adjusted Net Income divided by revenue.

Adjusted Earnings Per Share is Adjusted Net Income attributable to common stockholders divided by weighted average number of shares. The weighted average shares we use in computing Adjusted Earnings Per Share — basic is equal to our GAAP weighted average shares — basic and the weighted average shares we use in computing Adjusted Earnings Per Share — diluted is equal to either GAAP weighted average shares — basic or GAAP weighted average shares — diluted, depending on whether we have adjusted net loss or adjusted net income, respectively.

We also assess our performance by evaluating each cost and operating expense on our condensed consolidated statements of operations on a non-GAAP, or adjusted, basis to arrive at Adjusted Operating Income. The adjustments to these cost and operating expense items include acquisition related expenses, amortization of intangibles related to acquisitions, stock-based compensation expense, payroll tax expense related to stock-based compensation, financing related expenses, and as applicable, loss on abandonment and impairment of operating lease assets and charitable stock donation. Adjusted Operating Income is GAAP revenue less non-GAAP operating expenses.

We believe our Non-GAAP Measures are helpful to investors, analysts and other interested parties because they assist in providing a more consistent and comparable overview of our operations across our historical financial periods. Adjusted EBITDA is also a key measure we use to assess our financial performance and is also used for internal planning and forecasting purposes. In addition, Adjusted EBITDA, Adjusted Net Income and Adjusted Earnings Per Share are frequently used by analysts, investors and other interested parties to evaluate and assess performance.

The Non-GAAP Measures are presented for supplemental informational purposes only and should not be considered as alternatives or substitutes to financial information presented in accordance with GAAP. These measures have certain limitations in that they do not include the impact of certain expenses that are reflected in our condensed consolidated statements of operations that are necessary to run our business. Other companies, including other companies in our industry, may not use these measures or may calculate these measures differently than as presented herein, limiting their usefulness as comparative measures.

The following table presents a reconciliation of net (loss) income, the most directly comparable financial measure calculated in accordance with GAAP, to Adjusted EBITDA:

(dollars in thousands)

	Three Months Ended								Year Ended December 31,	
	December 31, 2021	September 30, 2021	June 30, 2021	March 31, 2021	December 31, 2020	September 30, 2020	June 30, 2020	March 31, 2020	2021	2020
Net (loss) income	\$ (39,914)	\$ (18,069)	\$ 31,061	\$ 1,668	\$ (298,274)	\$ (50,032)	\$ 27,337	\$ 27,346	\$ (25,254)	\$ (293,623)
Adjusted to exclude the following:										
Interest income	(17)	(13)	(13)	(16)	(20)	(24)	(41)	(75)	(59)	(160)
Interest expense	5,903	5,928	5,906	5,905	6,216	6,264	6,795	8,638	23,642	27,913
Income tax expense (benefit)	45,784	19,153	(37,305)	(12,555)	(7,360)	(17,894)	7,661	7,766	15,077	(9,827)
Depreciation and amortization	10,648	10,161	8,369	5,361	4,404	5,160	4,521	4,345	34,539	18,430
Other (income) expense, net	—	—	—	—	(2)	1	(16)	(5)	—	(22)
Financing related expenses ⁽¹⁾	217	134	58	257	13	—	188	1,118	666	1,319
Acquisition related expenses ⁽²⁾	5,084	1,714	3,022	3,048	3,642	2,481	780	463	12,868	7,366
Stock-based compensation expense ⁽³⁾	33,280	39,980	40,676	46,526	286,081	106,873	2,121	2,210	160,462	397,285
Charitable stock donation ⁽⁴⁾	—	—	—	—	41,721	—	—	—	—	41,721
Payroll tax expense related to stock-based compensation	1,266	2,150	2,016	828	11,682	323	22	59	6,260	12,086
Loss on abandonment and impairment of operating lease assets ⁽⁵⁾	—	650	780	—	961	—	—	—	1,430	961
Adjusted EBITDA	\$ 62,251	\$ 61,788	\$ 54,570	\$ 51,022	\$ 49,064	\$ 53,152	\$ 49,368	\$ 51,865	\$ 229,631	\$ 203,449
Adjusted EBITDA Margin	29.2%	31.7%	30.9%	31.8%	32.0%	37.8%	40.0%	38.9%	30.8%	36.9%

⁽¹⁾ Financing related expenses include third party fees related to proposed financings.

⁽²⁾ Acquisition related expenses include third party fees for actual or planned acquisitions, including related legal, consulting and other expenditures, and as applicable, retention bonuses to employees related to acquisitions and change in fair value of contingent consideration.

⁽³⁾ Non-cash expenses related to equity-based compensation programs, which vary from period to period depending on various factors including the timing, number and the valuation of awards.

⁽⁴⁾ Non-cash expense related to a donation of 1.1 million shares of our Class A common stock that was made to a charitable foundation in the fourth quarter of 2020.

⁽⁵⁾ Non-cash loss on the abandonment and impairment of operating lease assets related to certain office space that was abandoned or subleased.

The following tables present a reconciliation of net (loss) income, the most directly comparable financial measure calculated in accordance with GAAP, to Adjusted Net Income, and calculation of Adjusted Earnings Per Share:

(in thousands, except per share amounts)

	Three Months Ended								Year Ended December 31,	
	December 31, 2021	September 30, 2021	June 30, 2021	March 31, 2021	December 31, 2020	September 30, 2020	June 30, 2020	March 31, 2020	2021	2020
Net (loss) income	\$ (39,914)	\$ (18,069)	\$ 31,061	\$ 1,668	\$ (298,274)	\$ (50,032)	\$ 27,337	\$ 27,346	\$ (25,254)	\$ (293,623)
Adjusted to exclude the following:										
Amortization of intangibles related to acquisitions	5,286	5,703	4,868	2,476	2,307	3,651	3,280	3,421	18,333	12,659
Financing related expenses ⁽¹⁾	217	134	58	257	13	—	188	1,118	666	1,319
Acquisition related expenses ⁽²⁾	5,084	1,714	3,022	3,048	3,642	2,481	780	463	12,868	7,366
Stock-based compensation expense ⁽³⁾	33,280	39,980	40,676	46,526	286,081	106,873	2,121	2,210	160,462	397,285
Payroll tax expense related to stock-based compensation	1,266	2,150	2,016	828	11,682	323	22	59	6,260	12,086
Charitable stock donation ⁽⁴⁾	—	—	—	—	41,721	—	—	—	—	41,721
Loss on abandonment and impairment of operating lease assets ⁽⁵⁾	—	650	780	—	961	—	—	—	1,430	961
Income tax expense (benefit) on excluded items and adjusting for valuation allowance and excess tax benefits/deficiencies on stock-based compensation exercises	35,237	7,388	(47,410)	(22,961)	(15,919)	(27,661)	(1,438)	(1,439)	(27,746)	(46,457)
Adjusted net income	\$ 40,456	\$ 39,650	\$ 35,071	\$ 31,842	\$ 32,214	\$ 35,635	\$ 32,290	\$ 33,178	\$ 147,019	\$ 133,317
Less: Adjusted undistributed earnings allocated to convertible preferred stock	—	—	—	—	—	(11,698)	(11,466)	(11,749)	—	(34,913)
Adjusted net income attributable to common stockholders — basic	\$ 40,456	\$ 39,650	\$ 35,071	\$ 31,842	\$ 32,214	\$ 23,937	\$ 20,824	\$ 21,429	\$ 147,019	\$ 98,404
Add: Adjusted undistributed earnings allocated to holders of common stock	—	—	—	—	—	597	222	206	—	1,025
Adjusted net income attributable to common stockholders — diluted	\$ 40,456	\$ 39,650	\$ 35,071	\$ 31,842	\$ 32,214	\$ 24,534	\$ 21,046	\$ 21,635	\$ 147,019	\$ 99,429
Weighted average shares used in computing adjusted earnings per share:										
Weighted average shares — basic	414,068	411,223	408,363	406,170	401,459	241,061	230,160	229,880	409,981	274,696
Dilutive impact of stock options, restricted stock awards and restricted stock units	17,012	18,497	20,504	23,407	26,776	19,300	6,730	6,345	19,855	14,631
Weighted average shares — diluted	431,080	429,720	428,867	429,577	428,235	260,361	236,890	236,225	429,836	289,327
Adjusted earnings per share:										
Basic	\$ 0.10	\$ 0.10	\$ 0.09	\$ 0.08	\$ 0.08	\$ 0.10	\$ 0.09	\$ 0.09	\$ 0.36	\$ 0.36
Diluted	\$ 0.09	\$ 0.09	\$ 0.08	\$ 0.07	\$ 0.08	\$ 0.09	\$ 0.09	\$ 0.09	\$ 0.34	\$ 0.34

⁽¹⁾ Financing related expenses include third party fees related to proposed financings.

⁽²⁾ Acquisition related expenses include third party fees for actual or planned acquisitions, including related legal, consulting and other expenditures, and as applicable, retention bonuses to employees related to acquisitions and change in fair value of contingent consideration.

⁽³⁾ Non-cash expenses related to equity-based compensation programs, which vary from period to period depending on various factors including the timing, number and the valuation of awards.

⁽⁴⁾ Non-cash expense related to a donation of 1.1 million shares of our Class A common stock that was made to a charitable foundation in the fourth quarter of 2020.

⁽⁵⁾ Non-cash loss on the abandonment and impairment of operating lease assets related to certain office space that was abandoned or subleased.

Each cost and operating expense is adjusted for acquisition related expenses, amortization of intangibles related to acquisitions, stock-based compensation expense, payroll tax expense related to stock-based compensation, financing related expenses, and as applicable, loss on abandonment and impairment of operating lease assets and charitable stock donation.

(dollars in thousands)

	GAAP Three Months Ended December 31,		Adjusted Three Months Ended December 31,		GAAP Year Ended December 31,		Adjusted Year Ended December 31,	
	2021	2020	2021	2020	2021	2020	2021	2020
Cost of revenue	\$ 13,927	\$ 9,204	\$ 12,980	\$ 9,118	\$ 46,716	\$ 29,587	\$ 45,193	\$ 29,403
% of Revenue	6.5%	6.0%	6.1%	5.9%	6.3%	5.4%	6.1%	5.3%
Product development and technology	35,060	23,683	25,532	17,212	125,860	61,816	85,711	49,419
% of Revenue	16.4%	15.4%	12.0%	11.2%	16.9%	11.2%	11.5%	9.0%
Sales and marketing	106,491	74,940	101,003	71,879	370,217	255,135	346,921	246,300
% of Revenue	49.9%	48.8%	47.4%	46.8%	49.7%	46.3%	46.5%	44.7%
General and administrative	35,374	340,753	11,490	6,271	154,686	461,451	37,968	22,129
% of Revenue	16.6%	221.9%	5.4%	4.1%	20.8%	83.8%	5.1%	4.0%
Depreciation and amortization	10,648	4,404	5,362	2,097	34,539	18,430	16,206	5,771
% of Revenue	5.0%	2.9%	2.5%	1.4%	4.6%	3.3%	2.2%	1.0%
Operating income (loss)	11,756	(299,440)	56,889	46,967	13,406	(275,719)	213,425	197,678
% of Revenue	5.5%	(195.0%)	26.7%	30.6%	1.8%	(50.1%)	28.6%	35.9%

The following table presents a reconciliation of each non-GAAP, or adjusted, cost and expense measure to its most directly comparable financial measure calculated in accordance with GAAP:

(in thousands)

	Three Months Ended December 31,		Year Ended December 31,	
	2021	2020	2021	2020
Cost of revenue	\$ 13,927	\$ 9,204	\$ 46,716	\$ 29,587
Acquisition related expenses	(663)	—	(617)	—
Stock-based compensation expense	(258)	(86)	(798)	(184)
Payroll tax expense related to stock-based compensation	(26)	—	(108)	—
Adjusted cost of revenue	\$ 12,980	\$ 9,118	\$ 45,193	\$ 29,403
Product development and technology	\$ 35,060	\$ 23,683	\$ 125,860	\$ 61,816
Acquisition related expenses	(417)	(306)	(1,923)	(1,460)
Stock-based compensation expense	(8,434)	(6,165)	(35,090)	(10,937)
Payroll tax expense related to stock-based compensation	(677)	—	(3,136)	—
Adjusted product development and technology	\$ 25,532	\$ 17,212	\$ 85,711	\$ 49,419
Sales and marketing	\$ 106,491	\$ 74,940	\$ 370,217	\$ 255,135
Acquisition related expenses	(838)	(34)	(1,611)	(46)
Stock-based compensation expense	(4,487)	(3,027)	(20,645)	(8,789)
Payroll tax expense related to stock-based compensation	(163)	—	(1,040)	—
Adjusted sales and marketing	\$ 101,003	\$ 71,879	\$ 346,921	\$ 246,300
General and administrative	\$ 35,374	\$ 340,753	\$ 154,686	\$ 461,451
Financing related expenses	(217)	(13)	(666)	(1,319)
Acquisition related expenses	(3,166)	(3,302)	(8,717)	(5,860)
Stock-based compensation expense	(20,101)	(276,803)	(103,929)	(377,375)
Payroll tax expense related to stock-based compensation	(400)	(11,682)	(1,976)	(12,086)
Charitable stock donation	—	(41,721)	—	(41,721)
Loss on abandonment and impairment of operating lease assets	—	(961)	(1,430)	(961)
Adjusted general and administrative	\$ 11,490	\$ 6,271	\$ 37,968	\$ 22,129
Depreciation and amortization	\$ 10,648	\$ 4,404	\$ 34,539	\$ 18,430
Amortization of intangibles related to acquisitions	(5,286)	(2,307)	(18,333)	(12,659)
Adjusted depreciation and amortization	\$ 5,362	\$ 2,097	\$ 16,206	\$ 5,771
Operating income (loss)	\$ 11,756	\$ (299,440)	\$ 13,406	\$ (275,719)
Amortization of intangibles related to acquisitions	5,286	2,307	18,333	12,659
Financing related expenses	217	13	666	1,319
Acquisition related expenses	5,084	3,642	12,868	7,366
Stock-based compensation expense	33,280	286,081	160,462	397,285
Payroll tax expense related to stock-based compensation	1,266	11,682	6,260	12,086
Charitable stock donation	—	41,721	—	41,721
Loss on abandonment and impairment of operating lease assets	—	961	1,430	961
Adjusted operating income	\$ 56,889	\$ 46,967	\$ 213,425	\$ 197,678